Evidence map›Paper›PMID 36460769›Full record

ArticleScientific reports2022

Personalized health risk assessment based on single-cell RNA sequencing analysis of a male with 45, X/48, XYYY karyotype.

Magdalena Koczkowska, Marcin Jąkalski, Dorota Birkholz-Walerzak, Anna Kostecka, Mariola Iliszko, Magdalena Wójcik, Krzysztof Lewandowski, Katarzyna Milska-Musa, Patrick G Buckley, Kinga Drężek and 12 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 2 countries.

Magdalena Koczkowska *Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.
Marcin Jąkalski *3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Dorota Birkholz-Walerzak *Department of Paediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland.
Anna KosteckaFaculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.
Mariola IliszkoDepartment of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland.
Magdalena Wójcik3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Krzysztof LewandowskiDepartment of Laboratory Medicine, Medical University of Gdansk, Gdansk, Poland.
Katarzyna Milska-MusaDepartment of Quality of Life Research, Faculty of Health Sciences With the Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Gdansk, Poland.
Patrick G BuckleyGenomics Centre, Genuity Science, Dublin, Ireland.
Kinga Drężek3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Ulana Juhas3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Ewa KuziemskaDepartment of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland.
Agnieszka MaciejewskaDepartment of Forensic Medicine, Medical University of Gdansk, Gdansk, Poland.
Ryszard PawłowskiDepartment of Forensic Medicine, Medical University of Gdansk, Gdansk, Poland.
Bartosz WasągDepartment of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland.
Natalia Filipowicz3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Katarzyna Chojnowska3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Urszula Ławrynowicz3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Jan P DumanskiFaculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.
Beata S Lipska-Ziętkiewicz *Rare Diseases Centre, Medical University of Gdansk, Gdansk, Poland.
Jakub Mieczkowski *3P-Medicine Laboratory, Medical University of Gdansk, Gdansk, Poland.
Arkadiusz Piotrowski *Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland. arkadiusz.piotrowski@gumed.edu.pl.
Gdańsk Medical University · PLUniversity Clinical Centre · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numeric sex chromosome abnormalities are commonly associated with an increased cancer risk. Here, we report a 14-year-old boy with a rare mosaic 45, X/48, XYYY karyotype presenting with subtle dysmorphic features and relative height deficiency, requiring growth hormone therapy. As only 12 postnatal cases have been described so far with very limited follow-up data, to assess the proband's long-term prognosis, including cancer risk, we performed high-throughput single-cell RNA sequencing (scRNA-seq) analysis. Although comprehensive cytogenetic analysis showed seemingly near perfect balance between 45, X and 48, XYYY cell populations, scRNA-seq revealed widespread differences in genotype distribution among immune cell fractions, specifically in monocytes, B- and T-cells. These results were confirmed at DNA level by digital-droplet PCR on flow-sorted immune cell types. Furthermore, deregulation of predominantly autosomal genes was observed, including TCL1A overexpression in 45, X B-lymphocytes and other known genes associated with hematological malignancies. Together with the standard hematological results, showing increased fractions of monocytes and CD4+/CD8+T lymphocytes ratio, long-term personalized hemato-oncological surveillance was recommended in the reported patient.

Indexed as

NeoplasmsAdolescentHumansKaryotypeKaryotypingMaleRisk AssessmentSequence Analysis, RNA

Identifiers

PMID36460769
PMCPMC9718746
OpenAlexW4311121724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.